Current Synthetic and Systems Biology
Open Access

Biomarker development for allergic risk assessment

2^nd International Conference on Systems & Synthetic Biology

August 18-20, 2016 London, UK

Ying Mu

US Food and Drug Administration, USA

Posters & Accepted Abstracts: Curr Synthetic Sys Biol

Abstract :

There is an increase in the incidence of allergy/immunotoxicity-related post-market adverse events associated with medical devices. Biomarkers are commonly used in toxicology for risk assessment and clinically as diagnostic and monitoring tests. We developed a new in vitro model where human peripheral blood mononuclear cells (PBMC) serve as immunomodulators for biomarker development specifically for metal related allergenicity. The cell surface proteins were determined quantitatively. One of the purposes is to know whether the biomodulator system is transferable from the dendritic cell (DC) to the PBMC. Out of 12 surface proteins selected from the first tier selection that were screened, we found consistency of BM1 performance between DC and PBMC and other 3 proteins (BM2, BM3 and BM4) showed promise. The expression of BM1 was downregulated significantly following exposure to three well-known metallic allergens (Cobalt (II) chloride, nickel (II) sulfate, potassium dichromate (VI)), while the expression remained unchanged when exposed to two metallic non-allergens (lead (IV) acetate, magnesium (II) chloride) compared to untreated cells. Data from four healthy donors showed the same pattern. These results indicate that BM1 shows promise for use as a pre-clinical biomarker in screening potential allergenic risks to metal-containing devices. Further validation is planned.

Biography :

Email: Ying.Mu@fda.hhs.gov